World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
40439
World Ranking
6034
National Ranking
3225

Overview

John T. Isaacs is affiliated with Johns Hopkins University in the United States and has a research focus primarily in Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans several subfields including Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research, and Genetics.

The scientist's research covers main topics such as Prostate Cancer Treatment and Research, Hormonal and Reproductive Studies, Estrogen and Related Hormone Effects, Radiopharmaceutical Chemistry and Applications, Epigenetics and DNA Methylation, Ubiquitin and Proteasome Pathways, and PARP Inhibition in Cancer Therapy.

Recent notable publications include:

  • Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress (2020, Cell Reports)
  • Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (2020, Oncogene)
  • Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer (2021, JCI Insight)
  • Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy (2020, European Journal of Cancer)
  • Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC (2022, Journal of Clinical Investigation)

Their frequent coauthors include:

  • Samuel R. Denmeade
  • Peter S. Nelson
  • Angelo M. De Marzo
  • W. Nathaniel Brennen
  • Susan L. Dalrymple

John T. Isaacs has published extensively in several venues. The most frequent publication venues are:

  • The Prostate
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Oncogene
  • Cancer Research
  • Molecular Cancer Therapeutics

Best Publications

  • AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

    Emmanuel S. Antonarakis;Changxue Lu;Hao Wang;Brandon Luber

  • KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

    Jin-Tang Dong;P. W. Lamb;C. W. Rinker-Schaeffer;J. Vukanovic

  • Activation of programmed cell death in the rat ventral prostate after castration.

    Natasha Kyprianou;John T. Isaacs

  • Etiology and disease process of benign prostatic hyperplasia

    John Tod Isaacs;Donald S. Coffey

  • A history of prostate cancer treatment

    Samuel R. Denmeade;John T. Isaacs

  • Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene

    B. Levine;Qi Huang;J. T. Isaacs;J. C. Reed

  • Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

    Natasha Kyprianou;Hugh F. English;John T. Isaacs

  • Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.

    Samuel R. Denmeade;Xiaohui S. Lin;John T. Isaacs

  • Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

    Natasha Kyprianou;Hugh F. English;Nancy E. Davidson;John T. Isaacs

  • Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers

    J.T. Isaacs;J.T. Isaacs;W.B. Isaacs;W.B. Isaacs;W.F.J. Feitz;W.F.J. Feitz;J. Scheres;J. Scheres

  • Adaptation versus Selection as the Mechanism Responsible for the Relapse of Prostatic Cancer to Androgen Ablation Therapy as Studied in the Dunning R-3327-H Adenocarcinoma

    John T. Isaacs;Donald S. Coffey

  • Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death

    Natasha Kyprianou;John T. Isaacs

  • Antagonistic Effect of Androgen on Prostatic Cell Death

    J.T. Isaacs

  • Implication of cell kinetic changes during the progression of human prostatic cancer

    Richard R. Berges;Richard R. Berges;Jasminka Vukanovic;Jonathan I. Epstein;Marne CarMichel

  • Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss

    J T Dong;H Suzuki;S S Pin;G S Bova

  • The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.

    Yuzo Furuya;Per Lundmo;Per Lundmo;Alison D. Short;Donald L. Gill

  • The biology of hormone refractory prostate cancer. Why does it develop

    John T. Isaacs

  • Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer

    Samuel R. Denmeade;Carsten M. Jakobsen;Samuel Janssen;Saeed R. Khan

  • Clinical evidence for and implications of the multistep development of prostate cancer.

    H. Ballentine Carter;Steven Piantadosi;John T. Isaacs

  • Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration.

    Hugh F. English;Natasha Kyprianou;John T. Isaacs

Frequent Co-Authors

William B. Isaacs
William B. Isaacs Johns Hopkins University
Angelo M. De Marzo
Angelo M. De Marzo Johns Hopkins University School of Medicine
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Alan K. Meeker
Alan K. Meeker Johns Hopkins University School of Medicine
J. Carl Barrett
J. Carl Barrett AstraZeneca (United Kingdom)
Jack A. Schalken
Jack A. Schalken Radboud University
Peter S. Nelson
Peter S. Nelson Fred Hutchinson Cancer Research Center
Bertrand Tombal
Bertrand Tombal Université Catholique de Louvain
Jeffrey M. Karp
Jeffrey M. Karp Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens opportunities beyond becoming a traditional doctor. Whether your interests lie in healthcare management, advanced nursing, or pharmacy, there are diverse degree pathways available—many of which can be pursued online for added flexibility.

For those interested in leadership and operational roles, earning a health administration degree online is a popular route. These programs equip students with the skills needed to manage hospitals and healthcare systems efficiently.

Cost is a major factor for many prospective students. Understanding mha degree cost can help you make informed decisions about your educational investment.

Nursing professionals looking to achieve the highest level of clinical practice are exploring the cheapest online bsn to dnp programs. These accelerated programs allow nurses to advance their credentials with greater affordability.

Finally, aspiring pharmacists can pursue their passion through online options as well. Comparing online pharmacy school cost helps students identify programs that fit their budget and career goals.

Best Scientists Citing John T. Isaacs

Trending Scientists

Recently Published Articles